Nomura Upgrades Chugai Pharmaceutical (OTCMKTS:CHGCY) to “Hold”

Chugai Pharmaceutical (OTCMKTS:CHGCY) was upgraded by equities research analysts at Nomura to a “hold” rating in a report released on Tuesday, Zacks reports.

CHGCY has been the subject of several other reports. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Finally, The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Trading Up 0.4%

CHGCY opened at $21.57 on Tuesday. The company has a 50 day moving average of $22.16 and a 200 day moving average of $25.24. The company has a market cap of $71.00 billion, a PE ratio of 23.45 and a beta of 0.59. Chugai Pharmaceutical has a 12 month low of $20.43 and a 12 month high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings data on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. The business had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. Research analysts forecast that Chugai Pharmaceutical will post 0.96 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.